Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Wildes

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Nature Chemical Biology|June 25, 2021
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growthBianca J Lee, Jacob A Boyer, G Leslie Burnett, et al.
Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Protein Science : a Publication of the Protein Society|February 4, 2005
Protein folding: defining a "standard" set of experimental conditions and a preliminary kinetic data set of two-state proteinsKaren L Maxwell, David Wildes, Arash Zarrine-Afsar, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Nature Chemical Biology|June 25, 2021
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growthBianca J Lee, Jacob A Boyer, G Leslie Burnett, et al.
Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Science (New York, N.Y.)|July 24, 2025
A neomorphic protein interface catalyzes covalent inhibition of RAS<sup>G12D</sup> aspartic acid in tumorsCaroline Weller, G Leslie Burnett, Lingyan Jiang, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Protein Science : a Publication of the Protein Society|February 4, 2005
Protein folding: defining a "standard" set of experimental conditions and a preliminary kinetic data set of two-state proteinsKaren L Maxwell, David Wildes, Arash Zarrine-Afsar, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Pageof 3